- Home
- NXGL vs LPCN Comparison
NXGL vs LPCN Comparison
Compare NXGL & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXGL
- LPCN
- Stock Information
- Founded
- NXGL 1997
- LPCN 1997
- Country
- NXGL United States
- LPCN United States
- Employees
- NXGL N/A
- LPCN N/A
- Industry
- NXGL Medical/Dental Instruments
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- NXGL Health Care
- LPCN Health Care
- Exchange
- NXGL Nasdaq
- LPCN Nasdaq
- Market Cap
- NXGL 18.7M
- LPCN 18.2M
- IPO Year
- NXGL 2021
- LPCN N/A
- Fundamental
- Price
- NXGL $2.45
- LPCN $2.69
- Analyst Decision
- NXGL
- LPCN Strong Buy
- Analyst Count
- NXGL 0
- LPCN 1
- Target Price
- NXGL N/A
- LPCN $8.00
- AVG Volume (30 Days)
- NXGL 65.2K
- LPCN 60.8K
- Earning Date
- NXGL 11-10-2025
- LPCN 11-07-2025
- Dividend Yield
- NXGL N/A
- LPCN N/A
- EPS Growth
- NXGL N/A
- LPCN N/A
- EPS
- NXGL N/A
- LPCN N/A
- Revenue
- NXGL $11,672,000.00
- LPCN $4,208,119.00
- Revenue This Year
- NXGL $46.60
- LPCN N/A
- Revenue Next Year
- NXGL $47.96
- LPCN N/A
- P/E Ratio
- NXGL N/A
- LPCN N/A
- Revenue Growth
- NXGL 133.02
- LPCN N/A
- 52 Week Low
- NXGL $2.10
- LPCN $2.65
- 52 Week High
- NXGL $5.10
- LPCN $6.17
- Technical
- Relative Strength Index (RSI)
- NXGL 44.97
- LPCN 35.95
- Support Level
- NXGL $2.45
- LPCN $2.75
- Resistance Level
- NXGL $2.71
- LPCN $2.92
- Average True Range (ATR)
- NXGL 0.18
- LPCN 0.14
- MACD
- NXGL -0.01
- LPCN -0.04
- Stochastic Oscillator
- NXGL 24.53
- LPCN 7.14
About NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.